Analytical Data
-
Gene name
CGRP
- Application
-
Alternative Names
CGRP；CALC1;Calcitonin gene-related peptide 1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P06881
-
Expression Region
83-119aa
-
AA Sequence
ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF
-
Molecular Weight
35.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CGRP (Calcitonin Gene-Related Peptide) is a neuropeptide that plays a significant role in the regulation of vascular tone and nociception. It is primarily produced in the trigeminal ganglia and is involved in migraine pathophysiology, where it contributes to the dilation of blood vessels and the transmission of pain signals. The overexpression of CGRP during migraine attacks has prompted extensive research into its potential as a therapeutic target. The development of recombinant CGRP proteins serves as an essential tool for understanding its biological functions and interactions. These recombinant proteins enable researchers to investigate CGRP's role in both healthy and pathological conditions, elucidating the mechanisms underlying migraine and other disorders mediated by CGRP. Additionally, the creation of CGRP receptor antagonists and monoclonal antibodies targeting CGRP has emerged as a promising therapeutic strategy, leading to the introduction of innovative migraine treatments. The ongoing research around CGRP and its recombinant forms continues to unveil new insights, aiming to improve the efficacy of migraine prophylaxis and enhance the overall management of related pain disorders.
